At a Glance
Drug: Vancomycin hydrochloride IV powder, a high-alert antimicrobial requiring patient-specific dosing, kidney function assessment and therapeutic drug monitoring. This guide describes preparation only, not a universal empiric dosing prescription.
Reconstitution
| Vial | Sterile water to add | Concentration |
|---|---|---|
| 500 mg | 10 mL | 50 mg/mL |
| 1 g | 20 mL | 50 mg/mL |
These concentrated solutions must be further diluted before routine IV infusion. For the referenced product, dilute 500 mg in at least 100 mL of compatible fluid and 1 g in at least 200 mL. Compatible solutions listed include 0.9% sodium chloride and 5% dextrose; verify manufacturer and local policy.
Infusion and nursing checks
Administer by intermittent IV infusion over at least 60 minutes; many patients need a longer infusion based on dose and infusion-reaction risk. Avoid rapid infusion. Calculate the pump rate from final volume and prescribed time. Verify patient weight, serum creatinine, infection severity, cultures, line access, allergies and drug monitoring plan before administration.
Monitoring and cautions
For serious MRSA infections, dosing should be individualised using institutional AUC-guided therapeutic monitoring protocols where available; renal impairment, dialysis and obesity require specialist input. Watch for infusion-related flushing/hypotension, nephrotoxicity, ototoxicity, neutropenia and severe hypersensitivity. The label’s stability statements apply only to the cited formulation and storage conditions; use pharmacy-approved beyond-use limits.
Expanded Preparation and Therapeutic Monitoring Notes
Intravenous vancomycin requires patient-specific dosing and monitoring, especially in serious MRSA infection, unstable kidney function and concurrent nephrotoxic exposure. AUC-guided monitoring is preferred in many serious MRSA scenarios where local expertise and sampling support it; fixed trough targets should not be applied indiscriminately.
Reconstitution Versus Dilution
Reconstitution creates a concentrated solution from a powder vial; subsequent dilution creates the final infusion. For a label specifying 500 mg reconstituted with 10 mL, the nominal concentrate is 50 mg/mL. For 1 g with 20 mL, the nominal concentrate is also 50 mg/mL. Both require further dilution for intermittent IV infusion according to the product label. Final concentration depends on actual total volume, not simply the printed volume of the receiving bag.
Infusion Reaction and Monitoring
Rapid administration can produce flushing, itching and hypotension. Check the permitted concentration and infusion rate, observe the patient and document actual administration times. Review renal function, concurrent nephrotoxins, microbiology, therapeutic concentrations and sampling times. Oral vancomycin is not a substitute for IV treatment of systemic infections.
Primary Product Label
DailyMed / FDA-linked prescribing information. Preparation instructions are formulation-specific and must be verified against the locally stocked product.
MedBodh clinical education for trained healthcare professionals; not a patient-specific order. Verify institutional policy, renal adjustment, neonatal and pregnancy/lactation guidance.